Clinical trial
A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder
NCT03188185 is registered in ClinicalTrials.gov with Alkermes, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder
- Lead sponsor
- Alkermes, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- June 12, 2017
- Completion date
- March 5, 2020
- Enrollment
- 278 (actual)
- Sites
- 35
Conditions
As the registry lists them; a condition with its own page is linked.